Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Public ClinicalTrials.gov record NCT06800313. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1/2 Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
Study identification
- NCT ID
- NCT06800313
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 190 participants
Conditions and interventions
Conditions
Interventions
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 5, 2025
- Primary completion
- Jul 10, 2028
- Completion
- Jul 10, 2028
- Last update posted
- Aug 30, 2026
2025 – 2028
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rocky Mountain Cancer Center | Colorado Springs | Colorado | 80909 | Recruiting |
| Sarah Cannon Research Institute 1 | Denver | Colorado | 80218 | Recruiting |
| Yale University | New Haven | Connecticut | 06511 | Recruiting |
| Florida Cancer Specialists | Sarasota | Florida | 34232 | Recruiting |
| XCancer Research Network LCMC Health EJGH | Metairie | Louisiana | 70006 | Recruiting |
| Dana Farber Mass General Brigham Cancer Care Inc | Boston | Massachusetts | 02114 | Recruiting |
| South Texas Accelerated Research Therapeutics, LLC (START) | Grand Rapids | Michigan | 49546 | Recruiting |
| Urology Cancer Center, PC | Omaha | Nebraska | 68130 | Recruiting |
| Memorial Sloan Kettering Cancer Center | Long Island City | New York | 11101 | Recruiting |
| Associated Medical Professionals | Syracuse | New York | 13210 | Recruiting |
| Duke University Medical Center | Durham | North Carolina | 27710 | Recruiting |
| Carolina Urologic Research Center | Myrtle Beach | South Carolina | 29572 | Recruiting |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | Recruiting |
| Urology Associates | Nashville | Tennessee | 37209 | Recruiting |
| NEXT Oncology | Austin | Texas | 78758 | Recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| Virginia Clinical Research | Norfolk | Virginia | 23502 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06800313, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 30, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06800313 live on ClinicalTrials.gov.